Discover 332 paid clinical trials in New Mexico. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
New Mexico provides a wide selection of paid research opportunities for both healthy volunteers and individuals with specific health conditions. Leading research sites in Albuquerque, Santa Fe, and Las Cruces are actively recruiting, offering early access to innovative treatments and exceptional healthcare.
Filter
1
Filter results
Results: 332
Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
for
Hematopoietic and Lymphatic System Neoplasm,
Location: Charleston SC, Augusta GA, Greenville SC, Anderson SC,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06279013
Recruiting
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Location: Orange CT, Ridgewood NY, Cheektowaga NY, Fort Myers FL,
Sponsor: Alebund Pharmaceuticals
Sex: All
Age: 12+
Code: NCT06933472
Phase 3, Recruiting
WEAVE NM: Heart Health and Nutrition for Life
for
Hypertension
Location: Albuquerque NM
Sponsor: University of New Mexico
Sex: All
Age: 18 - 70+
Code: NCT07074145
Recruiting
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
for
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Location: St. John's, Bangor ME, Scarborough ME, Providence RI,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 1 - 30
Code: NCT04546399
Phase 2, Recruiting
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
for
RSV Infection
Location: Boston MA, Norfolk VA, Richmond VA,
Sponsor: Pfizer
Sex: All
Age: 0+
Code: NCT06866405
Phase 3, Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: St. John's, Boston MA, Norwich CT, New Haven CT, Quebec,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06943872
Phase 3, Recruiting
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
for
Adjustment Disorder
Location: Boston MA, Worcester MA, New York NY, Philadelphia PA,
Sponsor: Reunion Neuroscience Inc
Sex: All
Age: 18 - 70+
Code: NCT07002034
Phase 2, Recruiting
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
for
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,
Location: Boston MA, Saint Johnsbury VT, Lebanon NH, The Bronx NY,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06532279
Phase 2, Recruiting
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
for
B Acute Lymphoblastic Leukemia
Location: Halifax, Scarborough ME, Boston MA, Providence RI,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 1 - 46
Code: NCT06124157
Phase 2, Recruiting
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
for
Long COVID, Long COVID Syndrome, Long COVID-19 Syndrome, PASC,
Location: Albuquerque NM
Sponsor: University of New Mexico
Sex: All
Age: 18 - 70+
Code: NCT06940609
Phase 2, Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
for
Pancreatic Neuroendocrine Tumor (pNET),
Location: Boston MA, New York NY, Philadelphia PA,
Sponsor: Exelixis
Sex: All
Age: 18+
Code: NCT06943755
Phase 2, Phase 3, Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
for
Endometrial Cancer
Location: St. John's, Scarborough ME, Boston MA, Providence RI,
Sponsor: Merck Sharp & Dohme LLC
Sex: Female
Age: 18+
Code: NCT06952504
Phase 3, Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)